A Preclinical Review Found Cannabinoid Reinforcement Especially Sensitive to Experimental Conditions

A 2008 review described cannabinoid reward and reinforcement as difficult to characterize in animal models and often dependent on particular experimental conditions. A negative result in one setup cannot settle every question about abuse potential.

The model must define the behavior

Reinforcement and a rewarding subjective experience are related concepts but are measured differently. An animal experiment uses an operational task. It does not obtain the same information as a human account of motivation or pleasure.

Conditions can change what a model detects

The review emphasized that cannabinoid reinforcement was less straightforward to demonstrate than some comparator-drug effects. That observation calls for careful interpretation of preparation, task and exposure conditions. It does not establish that cannabinoids lack reinforcing properties or that every positive assay predicts a use disorder.

Dependence adds a different dimension

A model of withdrawal or repeated-exposure adaptation does not independently validate a reward assay. The review considered these properties together while retaining unresolved questions. Their biological overlap should not erase their distinct definitions.

Interpreting the evidence

The source supports reporting what an experimental system can and cannot detect. It does not establish a clinical risk ranking from one negative animal task or permit an individual's addiction diagnosis to be inferred from a general reinforcement finding.

Related reading: interpreting cannabis tolerance claims.

Research reference

Panagis G; Vlachou S; Nomikos GG (2008). Behavioral pharmacology of cannabinoids with a focus on preclinical models for studying reinforcing and dependence-producing properties. Current drug abuse reviews. doi:10.2174/1874473710801030350.

This analysis draws on the supplied review abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

ABHD6 Inhibition After Brain Injury Improved Several Outcomes in Mice Without Testing THC Treatment

Post-injury treatment with the ABHD6 inhibitor WWL70 improved motor, memory and tissue outcomes in a mouse traumatic-brain-injury model. The study investigated endogenous 2-AG signaling, rather than administering THC or testing marijuana as a treatment. A different breakdown enzyme was the intervention target ABHD6 contributes a smaller portion of 2-AG hydrolysis…

Spread the love

Read Article: ABHD6 Inhibition After Brain Injury Improved Several Outcomes in Mice Without Testing THC Treatment

Clonidine Pretreatment Reduced WIN Sensitivity Without Producing the Same Clonidine Tolerance in Isolated Ileum

Clonidine exposure reduced later sensitivity to WIN 55,212-2 in isolated guinea-pig ileum even though the tested clonidine incubations did not produce tolerance to clonidine's own effect. Cross-desensitization and within-drug tolerance were separable observations. Both drugs initially inhibited stimulated contractions The study used electrically evoked twitches in an organ-bath preparation. WIN,…

Spread the love

Read Article: Clonidine Pretreatment Reduced WIN Sensitivity Without Producing the Same Clonidine Tolerance in Isolated Ileum

URB597 Changed Morphine Tolerance and Passive-Avoidance Learning in Rats

A rat study found that URB597 prevented the tested development of morphine antinociceptive tolerance and alleviated morphine-related impairment on a passive-avoidance learning task. These were two separately measured outcomes of an endocannabinoid-enzyme intervention. Repeated morphine established the adaptation question The investigators administered morphine repeatedly and gave URB597 beforehand. Tolerance was…

Spread the love

Read Article: URB597 Changed Morphine Tolerance and Passive-Avoidance Learning in Rats

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us